Join to View Full Profile
8550 Datapoint DrSuite 200San Antonio, TX 78229
Phone+1 210-615-8308
Fax+1 210-615-8313
Dr. Randall is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Charles Randall graduated from UTMB followed by residency at Vanderbilt University and fellowship at Washington university. His research and clinical interest include inflammatory bowel disease, esophageal disorders, and functional and motility problems. He is a clinical professor of medicine at UT San Antonio and has published over 100 papers and has given over 500 lectures.
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Gastroenterology, 1991 - 1993
Vanderbilt University Medical CenterResidency, Internal Medicine, 1988 - 1991
University of Texas Medical Branch School of MedicineClass of 1988
Certifications & Licensure
TX State Medical License 1990 - 2026
Awards, Honors, & Recognition
- Best papers in category in 2005, 2022, and 2025. For 2005 and 22 American College of Gastroenterology; for 2025 American Gastroenterology Association, 2005, 2022, 2025
- Super Doctor SuperDoctors.com
Clinical Trials
- Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease Start of enrollment: 2013 Mar 01
- Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) Start of enrollment: 2016 May 19
Publications & Presentations
PubMed
- A Novel, IBS-Specific IgG ELISA-Based Elimination Diet in Irritable Bowel Syndrome: A Randomized, Sham-Controlled Trial.Prashant Singh, William D Chey, Will Takakura, Brooks D Cash, Brian E Lacy
Gastroenterology. 2025-01-31 - 2 citationsA Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients with Moderatel...Matthieu Allez, Bruce E Sands, Brian G Feagan, Geert D'Haens, Gert De Hertogh
Journal of Crohn's & Colitis. 2023-08-21 - 40 citationsAndecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients W...William J. Sandborn, Bal R. Bhandari, Charles Randall, Ziad Younes, Tomasz Romanczyk
Journal of Crohn's & Colitis. 2018-08-29
Journal Articles
- Multiple titles.Multiple co-authors, Different journals are available on request of CV.
Press Mentions
New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal CancerMay 2nd, 2025
Research History
- Too many trials and subsequent publications to list here.CV with all clinical trials and publications and presentations available upon request.1998 - 2025
Professional Memberships
- Member
- American College of Gastroenterology and American gastroenterology AssociationMember
Other Languages
- Spanish
Industry Relationships
- Clinical investigator, Bio PharmaRelationships with multiple pharmaceutical sponsorsDisclosure: Complete list available upon request1997 - 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
